Dr. Abou-Alfa on Trials Investigating Immunotherapy in HCC
In Partnership With:
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses trials investigating immunotherapy in hepatocellular carcinoma (HCC).
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses trials investigating immunotherapy in hepatocellular carcinoma (HCC).
The field of immunotherapy is moving very rapidly based on solid data, explains Abou-Alfa. Preclinical data demonstrate that evidence is there regarding PD-1/PD-L1 expression as well as other markers for checkpoint inhibitors.
The CheckMate-040 trial, which is investigating nivolumab (Opdivo) in patients with HCC, demonstrated that nearly 260 patients had a continued response rate of 20%.
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Related Content
